HER2Background: While the addition of targeted therapy to neoadjuvant chemotherapy (NACT) dramatically increases the rate of pathological complete response in HER2-positive breast cancer, no reduction in the rate of mastectomy has been observed in randomised studies.European journal of cancer: official ...
The addition of trastuzumab (T) and lapatinib (L) to neoadjuvant chemotherapy increases the pathological complete response (pCR) rate in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. We investigated the efficacy of T or L with neoadjuvant chemotherapy an...
The pCR rate in Ki-67 early non-responders in the Ki-67 arm was inferior to that in the control arm (44.1%; 31.4–56.7;=0.025).The standard chemotherapy protocol remains as the recommended strategy for patients with HER2-positive breast cancer.Clinical Trial Registration: UMIN-CTR as UMIN...
In order to elevate the burden on many patients with HER2-positive breast cancer, investigators tested whether a targeted therapy of T-DM1 would lead to a safer option than traditional therapy. “Currently, the standard of care neoadjuvant therapy for HER2-positive breast cancer is chemothera...
In this multi-center phase II trial, we evaluated the efficacy and safety of a quadruplet regimen (pembrolizumab, trastuzumab, and doublet chemotherapy) as first-line therapy for unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (AGC) (NCT...
PURPOSE: Neoadjuvant chemotherapy (NCT) plus anti-HER2 agents are the standard of care for locally advanced HER2-positive breast cancer. The aim of this study was to evaluate the prevalence and prognostic impact of HER2 loss in patients with HER2-positive disease treated with neoadjuvant therapy wi...
Design, Setting, and Participants Open-label, randomized (1:1) clinical trial including women with HER2-positive breast cancer. Chemotherapy was identical in the 2 groups, consisting of 3 cycles of 3-weekly docetaxel (either 80 or 100 mg/m2) plus trastuzumab for 9 weeks, followed by 3 cycle...
BACKGROUND: Trastuzumab, a monoclonal antibody against human epidermal growth factor receptor 2 (HER2; also known as ERBB2), was investigated in combination with chemotherapy for first-line treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer. METHODS: ToGA (Trastuzumab for...
Targeted Therapies for HER2-positive Breast Cancer Trastuzumab plus adjuvant chemotherapy for operable HER-2 positive breast cancer. N Engl J Med. 2005;353:1673–84. CrossRef Piccart-Gebhart MJ, ... MV Dieci,V Guarneri,CA Giorgi,... - 《Current Clinical Pathology》 被引量: 3发表: 2015年...
Braman, N. et al. Association of peritumoral radiomics with tumor biology and pathologic response to preoperative targeted therapy for HER2 (ERBB2)-positive breast cancer.JAMA Netw. Open2, e192561 (2019). PubMedPubMed CentralGoogle Scholar ...